Syngene International (NSE:SYNGENE) filed an intimation on 24 August 2026 under Regulation 30(6) of the SEBI LODR Regulations, 2015, disclosing a virtual one-on-one meeting with Entrust Family Office scheduled for 28 August 2026 at 12:00 PM IST, to be conducted from Bangalore.
Key Highlights
- Syngene International has scheduled a virtual one-on-one meeting with Entrust Family Office on 28 August 2026 at 12:00 PM IST.
- The intimation was filed pursuant to Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- The company has confirmed that no Unpublished Price Sensitive Information will be disclosed during the meeting.
- The filing was signed by Chethan Yogesh, Company Secretary and Compliance Officer of Syngene International Limited.
About the Company
Syngene International Limited (NSE:SYNGENE), headquartered in Bengaluru, Karnataka, is a leading contract research, development, and manufacturing organisation. The company serves global innovator pharmaceutical, biotechnology, and consumer products companies across discovery, development, and commercial manufacturing stages. Incorporated in 1993 and operating within the Biocon SEZ at Bommasandra Industrial Area, Syngene is listed on both BSE and NSE under the Pharma and Healthcare sector.
Announcement in Detail
Syngene International filed its intimation with both BSE Limited and the National Stock Exchange of India Limited on 24 August 2026, bearing reference number Syn/CS/SE/Reg 30/2026-27/Aug/03. The disclosure, made under Regulation 30(6) of the SEBI LODR Regulations, 2015, informs exchanges of a forthcoming interaction between company representatives and an institutional investor. The filing follows SEBI's mandatory requirement for listed companies to notify exchanges of such engagements in advance.
The scheduled engagement is a virtual one-on-one meeting with Entrust Family Office, to be held on 28 August 2026 at 12:00 PM IST, with Bangalore listed as the venue. Alongside the schedule, the company explicitly stated in the filing that no Unpublished Price Sensitive Information, as defined under SEBI's Prohibition of Insider Trading Regulations, will be shared or discussed during the course of the meeting. The company also confirmed that this information would be made available on the official company website.
Impact on Investors
Investors will note that this filing is a procedural disclosure mandated by SEBI and does not indicate any corporate action, change in financial guidance, or alteration in the company's business strategy. The filing shows that Syngene International is maintaining its obligations under the SEBI LODR framework by providing advance intimation of investor engagements to the exchanges.
Shareholders will observe that the company's confirmation of no UPSI disclosure during the meeting provides assurance that information shared with the institutional investor will not confer any informational advantage over the broader investing public. The disclosed terms indicate no material change in the company's capital structure, earnings outlook, or governance arrangements arising from this meeting.
Sector / Market Context
India's contract research and manufacturing services sector has seen sustained growth in recent years, with domestic CRAMS players attracting increased attention from global pharmaceutical companies seeking to diversify supply chains beyond traditional geographies. According to industry estimates cited by bodies such as FICCI and the Pharmaceuticals Export Promotion Council of India, India's pharmaceutical exports have consistently crossed USD 25 billion annually, reinforcing the strategic importance of research-linked service providers such as Syngene within the broader pharmaceutical value chain.